London Daily

Focus on the big picture.
Thursday, Oct 02, 2025

As countries blame each other for pandemic, firms act together on vaccine

As countries blame each other for pandemic, firms act together on vaccine

Chinese doctor working with German company says global collaboration as much as science will lead to Covid-19 vaccine.
When the German-made doses of an experimental Covid-19 vaccine arrived in Beijing, Dr Hui Aimin did not want to take any chances.

He hired three drivers to pick up the vaccine cargo – packed in dry ice at minus 70 degrees Celsius (minus 94 degrees Fahrenheit) – and take turns at the wheel of a special-purpose, temperature-controlled vehicle for the 1,000km drive south to Jiangsu province to begin one of China’s first clinical trials of an overseas-made Covid-19 vaccine.

“Eighteen hours after we passed customs clearance in Beijing, we gave the first subject the mRNA vaccine injection,” said Hui, senior vice-president, chief medical officer and president of global research and development at the Shanghai Fosun Pharmaceutical Group Co.

“This is my first experience with such speed dosing for the first subject in a clinical trial,” said Hui, a doctor with three decades of experience in research and development in the US, China and Japan.

The Jiangsu first-stage trials started in July with 144 adults, part of an agreement between Hui’s company, commonly known as Fosun Pharma, and the vaccine creator Germany’s BioNTech SE. Pfizer Inc. of the United States has partnered with BioNTech on Covid-19 vaccine development for the global market outside China.

The partnerships are an example of the international business collaboration taking place that is expected to allow broader access to safe and effective vaccines, even as relations between many countries have soured amid the pandemic.

Other pharmaceutical companies are in similar tie-ups against a backdrop of concern about supply shortages as the US, Britain and the European Union and others have scrambled to place bulk orders for first doses.

While Fosun Pharma started the Jiangsu trials on one of two BioNTech vaccines, its focus has since shifted to seeking regulatory approval for the second candidate, which is now in phase 3, or final trials, run by Pfizer and enrolling some 44,000 people worldwide.

That phase 3 candidate – selected for global trials because it produced fewer side effects than the candidate trialled in Jiangsu – could be among the first vaccines approved for use overseas and in China.

“If the vaccine is successful, it will be approved in China,” Hui said, adding that Fosun Pharma was now in the process of seeking approval to run a clinical trial of that candidate in China.

Pfizer’s CEO Albert Bourla said last month it would be known by the end of October if that vaccine – which uses novel mRNA (messenger ribonucleic acid) technology to provoke an immune response within the body – worked. This would make it among the first companies to report results on any of the 10 vaccines in final-stage trials around the world.

Hui is hopeful that if the global data shows that the vaccine is safe and effective it could be approved for use in China within a couple of months of US approval.

“Our plan is to run a phase 2 trial and bridge the data from the Chinese subjects with the global data,” he said, noting that both data sets would be needed for regulatory approval in China.

“So there will be a little time difference between our approval [in China] and the approval overseas … we are actively working with the agencies to try to shorten the difference.”

Fosun Pharma is among several Chinese companies in partnership with overseas Covid-19 vaccine makers.

In August, Shenzhen Kangtai Biological Products signed a licensing deal with British firm AstraZeneca, whose candidate is also in phase 3 trials. Kangtai would supply the vaccine to mainland China and have the capacity to produce at least 100 million doses by the end of 2020, the British company said.

Beijing Advaccine Biotechnology Co. formed a partnership with US firm Inovio Pharmaceuticals Inc. in January. Advaccine filed to start a phase 1 trial of the Inovio candidate in China last month, according to registry records.

Hui said Fosun Pharma wasted little time settling on vaccine development as part of their strategy to combat Covid-19. He recalls an hours-long company conference call on January 29, when new daily infections in China – the original epicentre of the outbreak – had begun to exceed 1,000.

“We really want to make the contribution to fighting the pandemic, and contribute to solving the global health crisis, and protect humanity, especially our Chinese people,” he said.

BioNTech was contacted that same day about a potential partnership. Hui said he had his eye on the firm for their cutting-edge mRNA technology.

In March, the companies announced a formal agreement to collaborate on the development and commercialisation of BioNTech’s Covid-19 vaccine – known as BNT162 – in mainland China, Hong Kong, Macau and Taiwan.

Hui said discussions were still taking place over how many doses from BioNTech facilities would be allocated to the Chinese market if the vaccine won approval. A deal to provide 10 million doses to Hong Kong and Macau from BioNTech’s European manufacturing facilities has already been signed.

The two companies were exploring how to ensure sufficient and timely supply to China, “including the possibility of jointly established manufacturing in China”, Hui said.

He hoped that among the 10 candidates currently in phase 3 trials, at least one would be available to the public by the end of this year. Such speed was possible because of science but also because of global collaboration, he said.

Hui points to Fosun Pharma’s example: developing a vaccine made by a foreign company, using data from global trials and contributing their own data to potentially get the vaccine approved.

“Fighting the pandemic, fighting against the virus – it requires global collaboration,” he said, adding that it was possible this winter could bring a hard-hitting second wave as the virus continued to spread globally.

“The vaccine development is really racing against time.”
Newsletter

Related Articles

0:00
0:00
Close
Trump Administration Launches “TrumpRx” Plan to Enable Direct Drug Sales at Deep Discounts
Trump Announces Intention to Impose 100 Percent Tariff on Foreign-Made Films
Altman Says GPT-5 Already Outpaces Him, Warns AI Could Automate 40% of Work
Singapore and Hong Kong Vie to Dominate Asia’s Rising Gold Trade
Trump Organization Teams with Saudi Developer on $1 Billion Trump Plaza in Jeddah
Manhattan Sees Surge in Office-to-Housing Conversions, Highest Since 2008
Switzerland and U.S. Issue Joint Assurance Against Currency Manipulation
Electronic Arts to Be Taken Private in Historic $55 Billion Buyout
Thomas Jacob Sanford Named as Suspect in Deadly Michigan Church Shooting and Arson
Russian Research Vessel 'Yantar' Tracked Mapping Europe’s Subsea Cables, Raising Security Alarms
New York Man Arrested After On-Air Confession to 2017 Parents’ Murders
U.S. Defense Chief Orders Sudden Summit of Hundreds of Generals and Admirals
Global Cruise Industry Posts Dramatic Comeback with 34.6 Million Passengers in 2024
Trump Claims FBI Planted 274 Agents at Capitol Riot, Citing Unverified Reports
India: Internet Suspended in Bareilly Amid Communal Clashes Between Muslims and Hindus
Supreme Court Extends Freeze on Nearly $5 Billion in U.S. Foreign Aid at Trump’s Request
Archaeologists Recover Statues and Temples from 2,000-Year-Old Sunken City off Alexandria
China Deploys 2,000 Workers to Spain to Build Major EV Battery Factory, Raising European Dependence
Speed Takes Over: How Drive-Through Coffee Chains Are Rewriting U.S. Coffee Culture
U.S. Demands Brussels Scrutinize Digital Rules to Prevent Bias Against American Tech
Ringo Starr Champions Enduring Beatles Legacy While Debuting Las Vegas Art Show
Private Equity’s Fundraising Surge Triggers Concern of European Market Shake-Out
Colombian President Petro Vows to Mobilize Volunteers for Gaza and Joins List of Fighters
FBI Removes Agents Who Kneeled at 2020 Protest, Citing Breach of Professional Conduct
Trump Alleges ‘Triple Sabotage’ at United Nations After Escalator and Teleprompter Failures
Shock in France: 5 Years in Prison for Former President Nicolas Sarkozy
Tokyo’s Jimbōchō Named World’s Coolest Neighbourhood for 2025
European Officials Fear Trump May Shift Blame for Ukraine War onto EU
BNP Paribas Abandons Ban on 'Controversial Weapons' Financing Amid Europe’s Defence Push
Typhoon Ragasa Leaves Trail of Destruction Across East Asia Before Making Landfall in China
The Personality Rights Challenge in India’s AI Era
Big Banks Rebuild in Hong Kong as Deal Volume Surges
Italy Considers Freezing Retirement Age at 67 to Avert Scheduled Hike
Italian City to Impose Tax on Visiting Dogs Starting in 2026
Arnault Denounces Proposed Wealth Tax as Threat to French Economy
Study Finds No Safe Level of Alcohol for Dementia Risk
Denmark Investigates Drone Incursion, Does Not Rule Out Russian Involvement
Lilly CEO Warns UK Is ‘Worst Country in Europe’ for Drug Prices, Pulls Back Investment
Nigel Farage Emerges as Central Force in British Politics with Reform UK Surge
Disney Reinstates ‘Jimmy Kimmel Live!’ after Six-Day Suspension over Charlie Kirk Comments
U.S. Prosecutors Move to Break Up Google’s Advertising Monopoly
Nvidia Pledges Up to $100 Billion Investment in OpenAI to Power Massive AI Data Center Build-Out
U.S. Signals ‘Large and Forceful’ Support for Argentina Amid Market Turmoil
Nvidia and Abu Dhabi’s TII Launch First AI-&-Robotics Lab in the Middle East
Vietnam Faces Up to $25 Billion Export Loss as U.S. Tariffs Bite
Europe Signals Stronger Support for Taiwan at Major Taipei Defence Show
Indonesia Court Upholds Military Law Amid Concerns Over Expanded Civilian Role
Larry Ellison, Michael Dell and Rupert Murdoch Join Trump-Backed Bid to Take Over TikTok
Trump and Musk Reunite Publicly for First Time Since Fallout at Kirk Memorial
Vietnam Closes 86 Million Untouched Bank Accounts Over Biometric ID Rules
×